Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month Low – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) hit a new 52-week low during trading on Monday . The stock traded as low as $16.37 and last traded at $16.56, with a volume of 39516 shares. The stock had previously closed at $17.17.

Analyst Upgrades and Downgrades

Several research analysts recently commented on KLRA shares. Weiss Ratings began coverage on Kailera Therapeutics in a research note on Friday, August 14th. They issued a “sell (d)” rating for the company. Leerink Partners began coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 target price on the stock. Wall Street Zen lowered Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, TD Cowen started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.75.

Kailera Therapeutics Stock Up 7.3%

The firm’s 50-day simple moving average is $19.20. The company has a market capitalization of $2.30 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Sell-side analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in shares of Kailera Therapeutics during the second quarter worth approximately $309,000. Frazier Life Sciences Management L.P. purchased a new stake in Kailera Therapeutics in the 2nd quarter valued at $24,233,000. Atlas Venture Life Science Advisors LLC purchased a new stake in Kailera Therapeutics in the 2nd quarter valued at $113,923,000. Finally, Wellington Management Group LLP acquired a new stake in Kailera Therapeutics during the 2nd quarter worth $64,308,000.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.